Federal Science and Technology Grants

This funding opportunity provides financial support for organizations to develop and demonstrate innovative robotics and AI technologies that improve efficiency and reduce costs in home construction, ultimately increasing housing availability across the United States.

This funding opportunity supports innovative research projects aimed at improving understanding and treatment of tuberous sclerosis complex, targeting areas such as neuropsychiatric disorders, tumor management, and patient care advancements.

This program provides funding to eligible educational and research institutions for purchasing specialized scientific equipment that enhances research capabilities in food and agricultural sciences.

This funding opportunity is designed for U.S.-based universities to establish a center focused on advancing ocean and coastal mapping technologies and education in partnership with NOAA.

This program provides funding to universities in eligible states to enhance their research capabilities in science and engineering that support the needs of the Department of Defense.

This grant provides financial support for U.S. college and university faculty to mentor graduate and upper-level undergraduate students in geologic mapping projects that enhance the nation's geological knowledge and data resources.

The NSF Research Traineeship (NRT) Program seeks proposals that explore ways for graduate students in research-based masters and doctoral degree programs to develop the skills, knowledge, and competencies needed to pursue a range of science, technology, engineering, and mathematics (STEM) careers. This solicitation describes a pilot for a potential new track for the existingNRT Programthat will support research and education projects that will result in a new masters degree, certificate, or a track within an existing masters or Ph.D. program with high industry relevance in at least one focus area identified in this pilot. This will be accomplished through an effective partnership among: (a) a non-R1 Institution of Higher Education (IHE) (lead institution), (b) an non-lead IHE (an R1 or non-R1) that has either an ongoing or completed NRT program in at least one of the focus areas defined for this pilot (see below), and (c) two to three industry partners in the same focus area(s). The overall purpose is to train the STEM workforce in focus areas specified in this solicitation by stimulating collaborations among non-R1 institutions, institutions with existing or completed NRT projects, and industry partners.

This funding opportunity supports organizations in managing a national database that tracks the health outcomes and experiences of individuals with spinal cord injuries, enhancing research and rehabilitation practices across the United States.

This grant provides funding for research on the genetic analysis of Agassiz's Desert Tortoise populations to support conservation efforts and military operations in California.

This funding opportunity provides financial support to early-stage researchers affiliated with U.S.-based institutions to initiate projects that align with NASA's space and Earth science priorities.

This funding opportunity supports researchers and organizations in validating biomarkers for neurological and neuromuscular disorders to improve clinical trials and patient care.

This funding opportunity supports U.S. higher education institutions with doctoral programs in health professions to enhance their research capabilities and address health disparities through collaborative research projects.

This funding opportunity provides financial support for U.S. institutions to conduct scientific research on extraterrestrial samples returned from space missions, enhancing our understanding of planetary materials and processes.

This funding opportunity provides financial assistance to public and nonprofit organizations to create or expand programs that help older adults and individuals with disabilities afford assistive technology, enabling them to live independently and participate fully in their communities.

The US Geological Survey is offering a funding opportunity to a CESU partner for research in co-production of knowledge about Pacific salmon populations and habitats in the Koyukuk, Nowitna Innoko National Wildlife Refuges and Gana-AYoo managed freshwaters.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Level 4. Funding Levels 1, 2, and 3 are available under other program announcements (HT942524BCRPBTA12 for Levels 1 and 2 and HT942524BCRPBTA3 for Level 3). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcements before submitting the pre-application. An application that does not meet the intent of Funding Level 4 will not be recommended for funding, even if it might meet the intent of a different funding level.The following is a general description, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement:Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. Large-scale trials, such as comparative effectiveness clinical trials, that will transform and revolutionize the clinical management and/or prevention of breast cancer and lead to unprecedented impact on patients lives, may fall under this mechanism. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical trial successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents. For proposed research that will require U.S. Food and Drug Administration (FDA) involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g., therapeutics) that meet regulatory compliance guidelines, proof of availability of and access to appropriate subject population(s), validated projections for patient recruitment, and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA, if applicable.Funding from this award mechanism must support a clinical trial. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Note: An invited oral presentation is a requirement for application review of Funding Level 4 projects, as described in Section II.D.2.b, Full Application Submission Content.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Level 4 applications unless they are clearly addressing distinct research questions. Applications where one PI is providing samples or investigational agents while the other PI is performing most or all of the research and analyses do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Consumer Advocates: Applications are required to include consumer advocate involvement. The research team must include two or more breast cancer consumer advocates, who will be integral throughout the planning and implementation of the research project. Consumer advocates should be involved in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer, and they should be active in a breast cancer advocacy organization. Their role in the project should be independent of their employment, and they cannot be employees of any of the organizations participating in the application. Their role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, breast cancer. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project.Key Aspects of the BCRP Breakthrough Award Level 4 Mechanism: Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of FDA processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312), Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international regulatory agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant regulatory agency by the Breakthrough Award Level 4 application submission deadline. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency by the Breakthrough Award Level 4 application submission deadline. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The types of awards made under the program announcement will be cooperative agreements (31 USC 6305) based on anticipated substantial involvement on the part of CDMRP. Substantial involvement includes assistance, guidance, coordination, and/or participation by CDMRP staff in project activities, including but not limited to, Milestone Meetings wherein recommendations for continued funding will be made based on overall study progress.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP BTA4 should not exceed $15M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $23.3M to fund approximately one Breakthrough Award Level 4 application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The Public Diplomacy Section (PD) of the U.S. Embassy in Luxembourg, U.S. Department of State, announces an open competition for organizations to submit applications to carry out programs strengthening bilateral ties between the United States and Luxembourg on Accelerating STEM and Climate Ambitions. The U.S. Embassy Luxembourg invites proposals from non-governmental organizations, think tanks, government institutions, academic institutions, and individuals for programs strengthening the bilateral ties between the United States and Luxembourg and Accelerating STEM and Climate Ambitions, including, but not limited to: Programs that raise awareness about space and satellite technology, space exploration, biotechnology, green technology, clean energy, climate change, the climate crisis, or sustainable finance. This could include educational programs for young people, trainings for educators, public debates, exhibits, speakers, etc. Educational programs with a focus on interactive STEM skills, such as computer programming, coding, and robotics, or programs about the importance of protecting the environment, clean air and water and sustainability measures. Projects that share American best practices in STEM and space research, climate change, sustainability, sustainable finance, renewables, environmental protection, or biotechnology by bringing U.S. experts to engage with Luxembourg audiences. All programs must engage Luxembourg audiences. All programs must include a U.S. element or connection with U.S. experts that will promote increased understanding of U.S. policy and perspectives. Any speaker paid with grant funding must hold U.S. citizenship. Please review the complete NOFO on the Funding Opportunities page on our website: https://lu.usembassy.gov/grants-program/ , or in the related documents tab on the announcement on grants.gov.

This competition provides funding and flight testing opportunities for U.S.-based individuals, teams, and organizations to develop innovative space technologies that address critical challenges identified by NASA.

The Defense Advanced Research Projects Agency (DARPA) is soliciting innovative proposals in the development of highly coherent sources of vacuum ultraviolet (VUV) radiation for clock-grade spectroscopy of the recently discovered thorium (229m-Th) nuclear isomeric transition. Proposed research should investigate innovative approaches that enable revolutionary advances in science, devices, or systems. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

The DOD Traumatic Brain Injury and Psychological Health, Emerging Topics Research Award aims to accelerate research in traumatic brain injury and psychological health, with the goal of developing new clinical applications, health care products, and guidelines for Service Members, their Families, Veterans, and the American public.